We found HR mutations in approximately 15% of the patient cohort (n = 85), compared with 23% for BRCA2, 13% for GATA3, 7% for BRCA1, and 3% for PTEN in the same breast cancer patient cohort. Here, BRCA2 is linked to breast carcinoma.